Sorry, you need to enable JavaScript to visit this website.

VYNDAQEL® OR VYNDAMAX™ (tafamidis meglumine or tafamidis) Patient Counseling Information


Advise the patient to read the FDA-approved patient labeling (Patient Information).


Report pregnancies to the Pfizer reporting line at 1-800-438-1985. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Use in Specific Populations (8.1)].


Advise females not to breastfeed during treatment with VYNDAQEL or VYNDAMAX [see Use in Specific Populations (8.2)].

Transthyretin Amyloidosis Outcome Survey (THAOS)

Advise all patients prescribed VYNDAQEL or VYNDAMAX of the availability of the Transthyretin Amyloidosis Outcome Survey (THAOS) registry, that their participation is voluntary, and involves long-term follow-up. THAOS is an international disease registry designed to assess disease progression, genotype/phenotype relationships, and the impact of interventions, including VYNDAQEL and VYNDAMAX on disease progression. For information regarding the registry, visit

This product's label may have been updated. For full prescribing information, please visit

What's New

No Current Announcements.

Contact Pfizer Medical

Report an Adverse Event


Please enter your search term(s) for VYNDAQEL® OR VYNDAMAX™